Abstract

A 16-year-old boy was admitted to our emergency department, in Lombardy, complaining of intense pain in his chest—radiating to his left arm—which had started 1 h earlier. The day before he had a fever of 38·3°C that decreased after 100 mg of nimesulide. He reported no other symptoms, no medical history, and no contact with anyone with confirmed COVID-19. We found his vital signs to be normal apart from his temperature which was raised at 38·5°C. On auscultation of the patient's chest, we heard normal heart sounds, no pericardial rub, and no abnormal respiratory signs. We found no lymphadenopathy, no rash, and no areas of localised tenderness on the chest wall. An electrocardiogram (ECG) showed inferolateral ST-segment elevation (figure) and a transthoracic echocardiography showed hypokinesia of the inferior and inferolateral segments of the left ventricle, with a preserved ejection fraction of 52%; no pericardial effusion was seen. Investigations showed raised high-sensitivity cardiac troponin I (9449 ng/L), creatine phosphokinase (671·0 U/L), C-reactive protein (32·5 mg/L), and lactate dehydrogenase (276·0 U/L) concentrations (appendix). The leucocyte count was 12·75 × 109 per L, the neutrophil count was 10·04 × 109 per L, and the lymphocyte count was 0·78 × 109 per L. We gave the boy aspirin to relieve his pain and transferred him to the coronary care unit with a working diagnosis of acute myocarditis. The patient's pain gradually improved and after 2 h had completely resolved. However, during the first night, he reported further chest pain; the ECG was repeated but no significant changes were seen (appendix). We started him on intravenous ibuprofen 600 mg three times a day and both his symptoms and raised temperature resolved. Tests for autoantibodies and cardiotropic viruses were negative (appendix). On day 3, a nasopharyngeal swab test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was positive, so we started hydroxychloroquine and antiviral therapy. Serial measurements of the patient's troponin concentration showed a gradual reduction from a peak of 16 862 ng/L on day 1, to 39 ng/L on day 8. The inflammatory markers also returned to normal and the ST-segment elevation on ECG resolved (appendix). On day 11—after nasopharyngeal swabs taken on 2 consecutive days were negative—MRI T2-weighted short-tau inversion recovery sequences showed changes supporting the diagnosis of acute myocarditis (figure; appendix). On day 12, he was well, asymptomatic, and allowed home. Notably, throughout the entire time he was in hospital, our patient did not have any of the signs or symptoms—apart from a fever—typically reported in COVID-19; his peripheral oxygen saturation levels remained within normal limits and two chest x-rays, on days 3 and 6, were clear (appendix). Paediatric patients reporting chest pain and other features suggestive of acute myocarditis—with or without respiratory symptoms—should, we believe, also be tested for SARS-CoV-2 (video). Contributors We were all involved in the care and management of the patient, and the writing and editing the manuscript. Written consent for publication was obtained from the patient and his parents. Download .pdf (1.67 MB) Help with pdf files Supplementary appendix eyJraWQiOiI4ZjUxYWNhY2IzYjhiNjNlNzFlYmIzYWFmYTU5NmZmYyIsImFsZyI6IlJTMjU2In0.eyJzdWIiOiIyZDRhMGZkNzJlNjBlMjUzMjE1Y2U0NjJiOGFjM2FkYyIsImtpZCI6IjhmNTFhY2FjYjNiOGI2M2U3MWViYjNhYWZhNTk2ZmZjIiwiZXhwIjoxNjc0ODYxODkwfQ.jsi0EXkWppwei0D6Vj5VR619I_5i4O7xMhA9zHn_79yPDpo5FaLU1HSwJaoFLueT8SLN62sboN9uykXTu0mWTwxQrmTNSzFBTT3kyv_kUU52agHxApICwa6T6uGQX80JX78fpJpEWIrFaX3dn51lWcLJ16G01bfnMnHyNmqkc_fmXBw62qoKGsoHBl_RYLjU_aSKNaslY5AVn4kE7rGnSQ-MURic7OBrZMnRTWdEPx-rrgNLbIILQLCBWRcUGP28GOBqYVc14IGTst58n-P81h8rYXLkytDhTaaq8d290T06r-IqLxz-LXwRXriFUwZvcE3Meqk2dWwIpDOhyTEofQ Download .mp4 (30.68 MB) Help with .mp4 files Supplementary videoChest pain and fever in a teenage with SARS-CoV-2 positive nasopharyngeal swabChest pain and fever: myocarditis with Covid-19https://youtu.be/HtTB9mZkIDo

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call